Dr Devon Christie, Medical and Therapeutic Services Director with Numinus, speaks to Psychedelic Health about the representation of women in the field of psychedelics – from...
In this article, Nina Patrick, Ph.D.
Using machine learning analysis, researchers have determined that a mystical and insightful psychedelic drug experience may be linked to long-term reductions in anxiety and depression symptoms.
With an increase in psychedelic research and clinical trials, it is becoming increasingly important to train psychedelic therapists.
Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...
As psychedelic research increases, and a number of policy developments across the likes of the US, Canada and Australia are now enabling the delivery of psychedelic...
University of Cincinnati researchers have examined post-treatment journals kept by participants in a smoking cessation study that found psychedelics were effective in helping some people quit...
PharmaDrug Inc.
Awakn Life Sciences has signed its first Licensing Partnership agreement in Europe with a healthcare consortium.
The US Food and Drug Administration (FDA) has given IND approval for a Phase 2b study of a synthetic formulation of 5-MeO-DMT – BPL-003.